<DOC>
	<DOCNO>NCT00023400</DOCNO>
	<brief_summary>Primary Objective : To define impact nelfinavir ( give 1250mg bid part combination antiretroviral regimen ) peak level area curve rifabutin rifabutin metabolite , 25-O-desacetyl rifabutin rifabutin give 300 mg bi-weekly part tuberculosis chemotherapy . Secondary Objectives : To compare pharmacokinetics nelfinavir give twice daily 1250 mg bid twice-weekly isoniazid rifabutin pharmacokinetics nelfinavir 1250 mg twice-daily historical HIV-infected patient receive isoniazid rifabutin . To evaluate correlation pharmacokinetic parameter rifabutin 25-O-desacetyl rifabutin occurrence toxicity attribute rifabutin patient HIV-related tuberculosis . To define detailed pharmacokinetics isoniazid give 15mg/kg 900 mg patient HIV-related tuberculosis . To attempt derive optimal sample time nelfinavir rifabutin pharmacokinetic study .</brief_summary>
	<brief_title>TBTC Study 23B : Intensive PK Nelfinavir Rifabutin Interaction Patients With HIV-TB</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Patients HIVrelated tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>